Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023

Loading...
Loading...

Upgrades

For Airbnb Inc ABNB, Argus Research upgraded the previous rating of Hold to Buy. Airbnb earned $0.48 in the fourth quarter, compared to $0.08 in the year-ago quarter. The stock has a 52-week-high of $179.09 and a 52-week-low of $81.91. At the end of the last trading period, Airbnb closed at $123.53.

For Celsius Holdings Inc CELH, Credit Suisse upgraded the previous rating of Neutral to Outperform. For the third quarter, Celsius Holdings had an EPS of $0.67, compared to year-ago quarter EPS of $0.03. The current stock performance of Celsius Holdings shows a 52-week-high of $122.24 and a 52-week-low of $38.31. Moreover, at the end of the last trading period, the closing price was at $90.02.

JP Morgan upgraded the previous rating for Revolution Medicines Inc RVMD from Neutral to Overweight. In the fourth quarter, Revolution Medicines showed an EPS of $0.63, compared to $0.71 from the year-ago quarter. At the moment, the stock has a 52-week-high of $31.37 and a 52-week-low of $14.08. Revolution Medicines closed at $24.37 at the end of the last trading period.

According to Piper Sandler, the prior rating for Broadmark Realty Capital Inc BRMK was changed from Underweight to Neutral. For the fourth quarter, Broadmark Realty Capital had an EPS of $0.09, compared to year-ago quarter EPS of $0.18. The stock has a 52-week-high of $8.91 and a 52-week-low of $3.52. At the end of the last trading period, Broadmark Realty Capital closed at $4.92.

Piper Sandler upgraded the previous rating for HomeTrust Bancshares Inc HTBI from Neutral to Overweight. For the second quarter, HomeTrust Bancshares had an EPS of $0.90, compared to year-ago quarter EPS of $0.68. The stock has a 52-week-high of $31.11 and a 52-week-low of $21.55. At the end of the last trading period, HomeTrust Bancshares closed at $28.52.

Goldman Sachs upgraded the previous rating for Krystal Biotech Inc KRYS from Neutral to Buy. In the fourth quarter, Krystal Biotech showed an EPS of $1.25, compared to $0.94 from the year-ago quarter. The stock has a 52-week-high of $85.65 and a 52-week-low of $47.67. At the end of the last trading period, Krystal Biotech closed at $78.14.

See all analyst ratings upgrades.

Downgrades

For Anywhere Real Estate Inc HOUS, Keefe, Bruyette & Woods downgraded the previous rating of Outperform to Market Perform. In the fourth quarter, Anywhere Real Estate showed an EPS of $0.85, compared to $0.38 from the year-ago quarter. The stock has a 52-week-high of $12.96 and a 52-week-low of $5.82. At the end of the last trading period, Anywhere Real Estate closed at $5.95.

Goldman Sachs downgraded the previous rating for Arconic Corp ARNC from Neutral to Sell. For the fourth quarter, Arconic had an EPS of $0.31, compared to year-ago quarter EPS of $0.25. The stock has a 52-week-high of $31.91 and a 52-week-low of $16.33. At the end of the last trading period, Arconic closed at $22.13.

B of A Securities downgraded the previous rating for Kosmos Energy Ltd KOS from Buy to Neutral. For the fourth quarter, Kosmos Energy had an EPS of $0.23, compared to year-ago quarter EPS of $0.13. The current stock performance of Kosmos Energy shows a 52-week-high of $8.55 and a 52-week-low of $4.42. Moreover, at the end of the last trading period, the closing price was at $8.55.

Argus Research downgraded the previous rating for Williams Companies Inc WMB from Buy to Hold. In the fourth quarter, Williams Companies showed an EPS of $0.53, compared to $0.39 from the year-ago quarter. At the moment, the stock has a 52-week-high of $37.97 and a 52-week-low of $28.30. Williams Companies closed at $30.70 at the end of the last trading period.

For Domino's Pizza Inc DPZ, Northcoast Research downgraded the previous rating of Buy to Neutral. For the fourth quarter, Domino's Pizza had an EPS of $4.43, compared to year-ago quarter EPS of $4.25. The current stock performance of Domino's Pizza shows a 52-week-high of $448.99 and a 52-week-low of $291.00. Moreover, at the end of the last trading period, the closing price was at $295.63.

For Dick's Sporting Goods Inc DKS, Citigroup downgraded the previous rating of Buy to Neutral. For the third quarter, Dick's Sporting Goods had an EPS of $2.60, compared to year-ago quarter EPS of $3.19. The current stock performance of Dick's Sporting Goods shows a 52-week-high of $138.43 and a 52-week-low of $63.45. Moreover, at the end of the last trading period, the closing price was at $129.76.

According to UBS, the prior rating for OGE Energy Corp OGE was changed from Buy to Neutral. For the fourth quarter, OGE Energy had an EPS of $0.25, compared to year-ago quarter EPS of $0.27. At the moment, the stock has a 52-week-high of $42.91 and a 52-week-low of $33.28. OGE Energy closed at $36.57 at the end of the last trading period.

According to Raymond James, the prior rating for Argo Group International Holdings Ltd ARGO was changed from Market Perform to Underperform. Argo Gr Intl Hldgs earned $2.69 in the fourth quarter, compared to $1.77 in the year-ago quarter. At the moment, the stock has a 52-week-high of $45.26 and a 52-week-low of $19.00. Argo Gr Intl Hldgs closed at $29.18 at the end of the last trading period.

B of A Securities downgraded the previous rating for DISH Network Corp DISH from Buy to Underperform. DISH Network earned $1.47 in the fourth quarter, compared to $0.87 in the year-ago quarter. The stock has a 52-week-high of $33.74 and a 52-week-low of $12.17. At the end of the last trading period, DISH Network closed at $12.20.

For LendingTree Inc TREE, Susquehanna downgraded the previous rating of Positive to Neutral. LendingTree earned $0.38 in the fourth quarter, compared to $0.14 in the year-ago quarter. The current stock performance of LendingTree shows a 52-week-high of $129.30 and a 52-week-low of $17.59. Moreover, at the end of the last trading period, the closing price was at $32.20.

DA Davidson downgraded the previous rating for Holley Inc HLLY from Buy to Neutral. In the third quarter, Holley showed an EPS of $0.04, compared to $0.12 from the year-ago quarter. At the moment, the stock has a 52-week-high of $14.68 and a 52-week-low of $1.88. Holley closed at $2.25 at the end of the last trading period.

For FuboTV Inc FUBO, Evercore ISI Group downgraded the previous rating of Outperform to In-Line. In the fourth quarter, FuboTV showed an EPS of $0.39, compared to $0.57 from the year-ago quarter. The current stock performance of FuboTV shows a 52-week-high of $8.86 and a 52-week-low of $1.61. Moreover, at the end of the last trading period, the closing price was at $2.00.

For Thomson Reuters Corp TRI, National Bank Financial Inc downgraded the previous rating of Outperform to Sector Perform. Thomson Reuters earned $0.73 in the fourth quarter, compared to $0.43 in the year-ago quarter. At the moment, the stock has a 52-week-high of $125.32 and a 52-week-low of $91.55. Thomson Reuters closed at $121.67 at the end of the last trading period.

William Blair downgraded the previous rating for Focus Financial Partners Inc FOCS from Outperform to Market Perform. For the fourth quarter, Focus Finl Partners had an EPS of $0.99, compared to year-ago quarter EPS of $0.94. The current stock performance of Focus Finl Partners shows a 52-week-high of $52.62 and a 52-week-low of $30.27. Moreover, at the end of the last trading period, the closing price was at $51.75.

Loading...
Loading...

Morgan Stanley downgraded the previous rating for Fulcrum Therapeutics Inc FULC from Overweight to Equal-Weight. Fulcrum Therapeutics earned $0.51 in the third quarter, compared to $0.57 in the year-ago quarter. The current stock performance of Fulcrum Therapeutics shows a 52-week-high of $24.79 and a 52-week-low of $3.21. Moreover, at the end of the last trading period, the closing price was at $5.80.

See all analyst ratings downgrades.

Initiations

With an Outperform rating, SVB Leerink initiated coverage on Disc Medicine Inc IRON. The price target seems to have been set at $36.00 for Disc Medicine. The stock has a 52-week-high of $25.59 and a 52-week-low of $15.00. At the end of the last trading period, Disc Medicine closed at $24.39.

With a Buy rating, Guggenheim initiated coverage on Structure Therapeutics Inc GPCR. The price target seems to have been set at $50.00 for Structure Therapeutics. The stock has a 52-week-high of $27.46 and a 52-week-low of $20.80. At the end of the last trading period, Structure Therapeutics closed at $24.00.

Cowen & Co. initiated coverage on AbCellera Biologics Inc ABCL with an Outperform rating. For the fourth quarter, AbCellera Biologics had an EPS of $0.10, compared to year-ago quarter EPS of $0.19. The current stock performance of AbCellera Biologics shows a 52-week-high of $14.97 and a 52-week-low of $5.42. Moreover, at the end of the last trading period, the closing price was at $8.43.

RBC Capital initiated coverage on IDEAYA Biosciences Inc IDYA with an Outperform rating. The price target for IDEAYA Biosciences is set to $25.00. In the third quarter, IDEAYA Biosciences showed an EPS of $0.04, compared to $0.31 from the year-ago quarter. The current stock performance of IDEAYA Biosciences shows a 52-week-high of $19.14 and a 52-week-low of $8.14. Moreover, at the end of the last trading period, the closing price was at $17.35.

For Magenta Therapeutics Inc MGTA, HC Wainwright & Co. initiated coverage, by setting the current rating at Neutral. Magenta Therapeutics earned $0.27 in the third quarter, compared to $0.30 in the year-ago quarter. The stock has a 52-week-high of $3.62 and a 52-week-low of $0.32. At the end of the last trading period, Magenta Therapeutics closed at $0.81.

With an Outperform rating, BMO Capital initiated coverage on Structure Therapeutics Inc GPCR. The price target seems to have been set at $40.00 for Structure Therapeutics. At the moment, the stock has a 52-week-high of $27.46 and a 52-week-low of $20.80. Structure Therapeutics closed at $24.00 at the end of the last trading period.

With a Buy rating, Jefferies initiated coverage on Structure Therapeutics Inc GPCR. The price target seems to have been set at $34.00 for Structure Therapeutics. The current stock performance of Structure Therapeutics shows a 52-week-high of $27.46 and a 52-week-low of $20.80. Moreover, at the end of the last trading period, the closing price was at $24.00.

Piper Sandler initiated coverage on OPAL Fuels Inc OPAL with an Overweight rating. The price target for OPAL Fuels is set to $12.00. The current stock performance of OPAL Fuels shows a 52-week-high of $12.35 and a 52-week-low of $5.82. Moreover, at the end of the last trading period, the closing price was at $7.94.

With an Overweight rating, Piper Sandler initiated coverage on Clean Energy Fuels Corp CLNE. The price target seems to have been set at $8.00 for Clean Energy Fuels. At the moment, the stock has a 52-week-high of $8.65 and a 52-week-low of $4.02. Clean Energy Fuels closed at $5.73 at the end of the last trading period.

Piper Sandler initiated coverage on Aemetis Inc AMTX with an Underweight rating. The price target for Aemetis is set to $3.00. For the third quarter, Aemetis had an EPS of $0.46, compared to year-ago quarter EPS of $0.55. At the moment, the stock has a 52-week-high of $16.06 and a 52-week-low of $3.62. Aemetis closed at $3.85 at the end of the last trading period.

With a Buy rating, Loop Capital initiated coverage on Axcelis Technologies Inc ACLS. The price target seems to have been set at $150.00 for Axcelis Technologies. In the fourth quarter, Axcelis Technologies showed an EPS of $1.71, compared to $1.05 from the year-ago quarter. At the moment, the stock has a 52-week-high of $129.71 and a 52-week-low of $46.41. Axcelis Technologies closed at $125.29 at the end of the last trading period.

With an Outperform rating, Oppenheimer initiated coverage on Nurix Therapeutics Inc NRIX. The price target seems to have been set at $25.00 for Nurix Therapeutics. For the fourth quarter, Nurix Therapeutics had an EPS of $0.87, compared to year-ago quarter EPS of $0.85. The stock has a 52-week-high of $19.91 and a 52-week-low of $7.52. At the end of the last trading period, Nurix Therapeutics closed at $8.98.

See all analyst ratings initiations.

Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
date
▲▼
ticker
▲▼
name
▲▼
Price Target
▲▼
Upside/Downside
▲▼
Recommendation
▲▼
Firm
▲▼
Posted In: UpgradesDowngradesInitiationIntraday UpdateAnalyst RatingsBZI-Ratings
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...